Literature DB >> 25051439

Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.

Shoji Ichikawa1, Amie K Gray, Leah R Padgett, Matthew R Allen, Erica L Clinkenbeard, Nicole M Sarpa, Kenneth E White, Michael J Econs.   

Abstract

Fibroblast growth factor 23 (FGF23) is a hormone that inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D biosynthesis. The FGF23 subtilisin-like proprotein convertase recognition sequence ((176)RHTR(179)↓) is protected by O-glycosylation through ppGalNAc-T3 (GALNT3) activity. Thus, inactivating GALNT3 mutations render FGF23 susceptible to proteolysis, thereby reducing circulating intact hormone levels and leading to hyperphosphatemic familial tumoral calcinosis. To further delineate the role of glycosylation in the Fgf23 function, we generated an inducible FGF23 transgenic mouse expressing human mutant FGF23 (R176Q and R179Q) found in patients with autosomal dominant hypophosphatemic rickets (ADHR) and bred this animal to Galnt3 knockout mice, a model of familial tumoral calcinosis. Due to the low intact Fgf23 level, Galnt3 knockout mice with wild-type Fgf23 alleles were hyperphosphatemic. In contrast, carriers of the mutant FGF23 transgene, regardless of Galnt3 mutation status, had significantly higher serum intact FGF23, resulting in severe hypophosphatemia. Importantly, serum phosphorus and FGF23 were comparable between transgenic mice with or without normal Galnt3 alleles. To determine whether the presence of the ADHR mutation could improve biochemical and skeletal abnormalities in Galnt3-null mice, these mice were also mated to Fgf23 knock-in mice, carrying heterozygous or homozygous R176Q ADHR Fgf23 mutations. The knock-in mice with functional Galnt3 had normal Fgf23 but were slightly hypophosphatemic. The stabilized Fgf23 ADHR allele reversed the Galnt3-null phenotype and normalized total Fgf23, serum phosphorus, and bone Fgf23 mRNA. However, the skeletal phenotype was unaffected. In summary, these data demonstrate that O-glycosylation by ppGaINAc-T3 is only necessary for proper secretion of intact Fgf23 and, once secreted, does not affect Fgf23 function. Furthermore, the more stable Fgf23 ADHR mutant protein could normalize serum phosphorus in Galnt3 knockout mice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25051439      PMCID: PMC4164931          DOI: 10.1210/en.2014-1199

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

3.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

4.  A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.

Authors:  Shoji Ichikawa; Kenneth W Lyles; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

5.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

6.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

7.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Authors:  Takashi Shimada; Takanori Muto; Itaru Urakawa; Takashi Yoneya; Yuji Yamazaki; Katsuya Okawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

8.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.

Authors:  Orit Topaz; Daniel L Shurman; Reuven Bergman; Margarita Indelman; Paulina Ratajczak; Mordechai Mizrachi; Ziad Khamaysi; Doron Behar; Dan Petronius; Vered Friedman; Israel Zelikovic; Sharon Raimer; Arieh Metzker; Gabriele Richard; Eli Sprecher
Journal:  Nat Genet       Date:  2004-05-09       Impact factor: 38.330

9.  Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.

Authors:  Xiuying Bai; Dengshun Miao; Jiarong Li; David Goltzman; Andrew C Karaplis
Journal:  Endocrinology       Date:  2004-07-29       Impact factor: 4.736

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  10 in total

Review 1.  Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics.

Authors:  Erica L Clinkenbeard; Kenneth E White
Journal:  Bone       Date:  2017-01-31       Impact factor: 4.398

2.  Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.

Authors:  Shilpa Sharma; Ronit Katz; Charles Ginsberg; Alexander Bullen; Volker Vallon; Scott Thomson; Orson W Moe; Andrew N Hoofnagle; Peter W de Leeuw; Abraham A Kroon; Alfons J H M Houben; Joachim H Ix
Journal:  J Bone Miner Res       Date:  2022-04-25       Impact factor: 6.390

3.  Systemic Control of Bone Homeostasis by FGF23 Signaling.

Authors:  Erica L Clinkenbeard; Kenneth E White
Journal:  Curr Mol Biol Rep       Date:  2016-02-03

4.  FGF23 Synthesis and Activity.

Authors:  Megan L Noonan; Kenneth E White
Journal:  Curr Mol Biol Rep       Date:  2019-01-17

Review 5.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Authors:  Daniel Edmonston; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2019-09-13       Impact factor: 28.314

6.  Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels.

Authors:  Lina Song; Adam D Linstedt
Journal:  Elife       Date:  2017-03-31       Impact factor: 8.140

Review 7.  Npt2a as a target for treating hyperphosphatemia.

Authors:  Linto Thomas; Jessica A Dominguez Rieg; Timo Rieg
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

8.  In Vivo Analysis of the Contribution of Proprotein Convertases to the Processing of FGF23.

Authors:  Omar Al Rifai; Delia Susan-Resiga; Rachid Essalmani; John W M Creemers; Nabil G Seidah; Mathieu Ferron
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

9.  Genetic Knockout and Rescue Studies in Mice Unravel Abnormal Phosphorus Threshold in Hypophosphatemic Rickets.

Authors:  Cheryl P Sanchez; Subburaman Mohan
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

Review 10.  Research Models for Studying Vascular Calcification.

Authors:  Jaqueline Herrmann; Milen Babic; Markus Tölle; Markus van der Giet; Mirjam Schuchardt
Journal:  Int J Mol Sci       Date:  2020-03-23       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.